Literature DB >> 23881739

Cross-species sensitivity to a novel androgen receptor agonist of potential environmental concern, spironolactone.

Carlie A LaLone1, Daniel L Villeneuve, Jenna E Cavallin, Michael D Kahl, Elizabeth J Durhan, Elizabeth A Makynen, Kathleen M Jensen, Kyle E Stevens, Megan N Severson, Chad A Blanksma, Kevin M Flynn, Philip C Hartig, Jonne S Woodard, Jason P Berninger, Teresa J Norberg-King, Rodney D Johnson, Gerald T Ankley.   

Abstract

Spironolactone is a pharmaceutical that in humans is used to treat conditions like hirsutism, various dermatologic afflictions, and female-pattern hair loss through antagonism of the androgen receptor. Although not routinely monitored in the environment, spironolactone has been detected downstream of a pharmaceutical manufacturer, indicating a potential for exposure of aquatic species. Furthermore, spironolactone has been reported to cause masculinization of female western mosquitofish, a response indicative of androgen receptor activation. Predictive methods to identify homologous proteins to the human and western mosquitofish androgen receptor suggest that vertebrates would be more susceptible to adverse effects mediated by chemicals like spironolactone that target the androgen receptor compared with invertebrate species that lack a relevant homolog. In addition, an adverse outcome pathway previously developed for activation of the androgen receptor suggests that androgen mimics can lead to reproductive toxicity in fish. To assess this, 21-d reproduction studies were conducted with 2 fish species, fathead minnow and Japanese medaka, and the invertebrate Daphnia magna. Spironolactone significantly reduced the fecundity of medaka and fathead minnows at 50 μg/L, whereas daphnia reproduction was not affected by concentrations as large as 500 μg/L. Phenotypic masculinization of females of both fish species was observed at 5 μg/L as evidenced by formation of tubercles in fathead minnows and papillary processes in Japanese medaka. Effects in fish occurred at concentrations below those reported in the environment. These results demonstrate how a priori knowledge of an adverse outcome pathway and the conservation of a key molecular target across vertebrates can be utilized to identify potential chemicals of concern in terms of monitoring and highlight potentially sensitive species and endpoints for testing.
© 2013 SETAC.

Entities:  

Keywords:  Adverse outcome pathway; Endocrine disruption; Pharmaceutical; Reproductive toxicity; Spironolactone

Mesh:

Substances:

Year:  2013        PMID: 23881739     DOI: 10.1002/etc.2330

Source DB:  PubMed          Journal:  Environ Toxicol Chem        ISSN: 0730-7268            Impact factor:   3.742


  10 in total

1.  Adverse outcome pathway development II: best practices.

Authors:  Daniel L Villeneuve; Doug Crump; Natàlia Garcia-Reyero; Markus Hecker; Thomas H Hutchinson; Carlie A LaLone; Brigitte Landesmann; Teresa Lettieri; Sharon Munn; Malgorzata Nepelska; Mary Ann Ottinger; Lucia Vergauwen; Maurice Whelan
Journal:  Toxicol Sci       Date:  2014-12       Impact factor: 4.849

2.  Application of in silico and in vitro methods in the development of adverse outcome pathway constructs in wildlife.

Authors:  Judith C Madden; Vera Rogiers; Mathieu Vinken
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2014-11-19       Impact factor: 6.237

Review 3.  Leveraging existing data for prioritization of the ecological risks of human and veterinary pharmaceuticals to aquatic organisms.

Authors:  Carlie A LaLone; Jason P Berninger; Daniel L Villeneuve; Gerald T Ankley
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2014-11-19       Impact factor: 6.237

4.  Estimating Intermittent Individual Spawning Behavior via Disaggregating Group Data.

Authors:  Joel Nishimura; Rebecca Smith; Kathleen Jensen; Gerald Ankley; Karen Watanabe
Journal:  Bull Math Biol       Date:  2017-12-11       Impact factor: 1.758

5.  Metabolomics for informing adverse outcome pathways: Androgen receptor activation and the pharmaceutical spironolactone.

Authors:  J M Davis; D R Ekman; D M Skelton; C A LaLone; G T Ankley; J E Cavallin; D L Villeneuve; T W Collette
Journal:  Aquat Toxicol       Date:  2017-01-16       Impact factor: 4.964

6.  Quantitative cross-species extrapolation between humans and fish: the case of the anti-depressant fluoxetine.

Authors:  Luigi Margiotta-Casaluci; Stewart F Owen; Rob I Cumming; Anna de Polo; Matthew J Winter; Grace H Panter; Mariann Rand-Weaver; John P Sumpter
Journal:  PLoS One       Date:  2014-10-22       Impact factor: 3.240

Review 7.  Critical Review of Read-Across Potential in Testing for Endocrine-Related Effects in Vertebrate Ecological Receptors.

Authors:  Margaret E McArdle; Elaine L Freeman; Jane P Staveley; Lisa S Ortego; Katherine K Coady; Lennart Weltje; Arnd Weyers; James R Wheeler; Audrey J Bone
Journal:  Environ Toxicol Chem       Date:  2020-03-04       Impact factor: 3.742

8.  Combined Naïve Bayesian, Chemical Fingerprints and Molecular Docking Classifiers to Model and Predict Androgen Receptor Binding Data for Environmentally- and Health-Sensitive Substances.

Authors:  Alfonso T García-Sosa; Uko Maran
Journal:  Int J Mol Sci       Date:  2021-06-22       Impact factor: 5.923

Review 9.  The pros and cons of ecological risk assessment based on data from different levels of biological organization.

Authors:  Jason R Rohr; Christopher J Salice; Roger M Nisbet
Journal:  Crit Rev Toxicol       Date:  2016-06-24       Impact factor: 6.184

10.  Chronic Embryo-Larval Exposure of Fathead Minnows to the Pharmaceutical Drug Metformin: Survival, Growth, and Microbiome Responses.

Authors:  Joanne L Parrott; Victoria E Restivo; Karen A Kidd; Juliet Zhu; Kallie Shires; Stacey Clarence; Hufsa Khan; Cheryl Sullivan; Grazina Pacepavicius; Mehran Alaee
Journal:  Environ Toxicol Chem       Date:  2021-06-02       Impact factor: 4.218

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.